bluuebunny/crossref_metadata_2025_split huggingface dataset:
Epidemiology and risk factors for mammary tumours in female cats
Authors: Pickard Price P. , Stell A. , O'Neill D. , Church D. , Brodbelt D. 
Published: April 2023

ObjectivesThis study aimed to estimate the incidence and risk factors for mammary tumours in female cats attending UK primary‐care practices. The study hypothesised that middle‐aged, intact and certain breeds are associated with increased mammary tumour risk.Materials and MethodsA case–control study design identified mammary tumour cases by assessment of electronic patient records, nested within a denominator population of 259,869 female cats attending 886 primary‐care VetCompass participating veterinary practices in the UK in 2016.ResultsFrom 2858 potential mammary tumour cases identified within the denominator, 270 cats met the case definition, giving an incidence risk of 104 per 100,000 (0.104%, 95% confidence interval 0.092 to 0.117%) during 2016. In the risk factor analysis increasing age, purebred compared to crossbred and veterinary group were associated with increased odds of mammary tumour. Median survival after the diagnosis of mammary tumour cats was 18.7 months.Clinical SignificanceThe current study provides an updated estimate of the incidence of mammary cancer in cats seen in primary care veterinary practice in the UK with increasing risk seen in older cats and with purebred status. This study can aid veterinary surgeons to identify cats at greater risk of mammary tumour and advise on survival after diagnosis.
Identification of a novel sporadic U2HR pathogenic variant in a patient with Marie Unna hereditary hypotrichosis
Authors: Braun Tatjana , Wehner Maria , Teichler Anne , Betz Regina C. , Hoeger Peter H. 
Published: April 2023

AbstractMarie Unna hereditary hypotrichosis (MUHH) is a rare autosomal dominant hair loss disorder characterized by coarse, wiry, and twisted hair developing during early childhood, and followed by progressive hair loss with puberty. We report a sporadic case of a 4‐year‐old boy with clinical features suggestive of MUHH, in whom we identified the new pathogenic variant c.67C>T; p.(Gln23*) in U2HR. This finding extends the known spectrum of U2HR variants underlying MUHH and increases genetic information for further genotype–phenotype correlation.
Complete denture rehabilitation for a patient with Parkinson's disease using clinical strategies: A case report
Authors: Ribeiro Anne Kaline Claudino , Lemos Luisa Madeira , de Aquino Luana Maria Martins , Costa Rayanna Thayse Florêncio , de Moraes Sandra Lúcia Dantas , Carreiro Adriana da Fonte Porto 
Published: April 2023

AbstractObjectiveTo present clinical strategies for prosthetic rehabilitation with complete dentures (CDs) of a Parkinson's disease patient.Case reportAn 82‐year‐old patient sought the Department of Dentistry at UFRN, reporting retention dissatisfaction and hamper to the mandibular CD adaptation. Patient‐reported a dry mouth sensation, and exhibited disordered mandibular movements, tremors, and resorbed mandibular ridge. Aiming retention and stability, double molding with zinc enolic oxide impression paste, neutral zone technique, and non‐anatomic teeth were proposed as clinical strategies. At delivery, identification and relief in the supercompression areas were performed to facilitate the acceptance and use of the new dentures.ConclusionThe strategies promoted patient satisfaction regarding retention, stability, and comfort. This treatment may be considered for the rehabilitation of Parkinson's disease patients, favoring the adaptation process.
Supplemental Figure 5 from Radiation Protection of the Gastrointestinal Tract and Growth Inhibition of Prostate Cancer Xenografts by a Single Compound
Authors: Alexeev Vitali , Lash Elizabeth , Aguillard April , Corsini Laura , Bitterman Avi , Ward Keith , Dicker Adam P. , Linnenbach Alban , Rodeck Ulrich 
Published: April 2023

<p>Supplemental Figure 5:	Effects of RTA 408 on morphological appearance of normal prostate epithelial cells (PrEC), normal human keratinocytes (NHEK-1) and PC3 cells (scale bars 100 μM). RTA 408 was added to cultures for 72 h at the concentrations indicated.</p>
Supplementary Materials and Methods and Supplementary Tables S1-S5 from α<sub>V</sub>β<sub>3</sub> Integrin-Targeted Radionuclide Therapy with <sup>64</sup>Cu-cyclam-RAFT-c(-RGDfK-)<sub>4</sub>
Authors: Jin Zhao-Hui , Furukawa Takako , Degardin Mélissa , Sugyo Aya , Tsuji Atsushi B. , Yamasaki Tomoteru , Kawamura Kazunori , Fujibayashi Yasuhisa , Zhang Ming-Rong , Boturyn Didier , Dumy Pascal , Saga Tsuneo 
Published: April 2023

<p>Supplementary Files contain (1) Supplementary Materials and Methods for ï�¡Vï�¢3 expression analysis, autoradiography and histological analysis, and hematology and hepatorenal function; (2) Supplementary Tables S1-S5; and (3) Supplementary Figures S1-S5.	Table S1ï€­Effects of 37 MBq (1 nmol) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 {plus minus} GF/Lys on hepatorenal functions of U87MG tumor-bearing mice; Table S2ï€­Blood cell counts of U87MG tumor-bearing mice at various time points post-injection of 37 MBq (1 nmol) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 {plus minus} GF/Lys; Table S3ï€­Blood cell counts of U87MG tumor-bearing mice at various time points after single dose administrations of 37 and 74 MBq of 64Cu-cyclam-RAFT-c(-RGDfK-)4; Table S4ï€­Effects of 74 MBq (2 nmol) of 64Cu-cyclam-RAFT-c(-RGDfK-)4 + GF/Lys on hepatorenal functions of normal mice; Table S5ï€­Human absorbed doses extrapolated from the biodistribution data of 64Cu-cyclam-RAFT-c(-RGDfK-)4 in U87MG tumor-bearing mice</p>
Abstract 49: Comparison of subcutaneous and orthotopic tumor growth in syngeneic mouse models of ovarian and renal cancer
Authors: Suominen Mari I. , Zdrojewska Justyna , Konkol Yvonne , Fagerlund Katja M. , Ristola Mervi , Rissanen Jukka P. 
Published: April 2023

Abstract
Oncology drug development has markedly lower success rate (3.4%) than other indications (20.9%) as reported by Wong, Siah and Lo in 2019. Animal models are often pointed at as the culprits for failure in clinical trials. While better animal models for cancer are needed and constantly developed, the incentive of drug developers to use those might not be clear, because the regulatory authorities do not require it. Subcutaneous tumors have earned their place in drug development but adding more sophisticated models to the testing panel before entering the clinical phase should improve the success rate. We present here the properties of subcutaneous and orthotopic tumor growth in two syngeneic models. HM-1 murine ovarian cancer cells were inoculated subcutaneously (s.c.) and intraperitoneally (representing the stage of intraperitoneal carcinomatosis) and murine renal adenocarcinoma Renca cells s.c. and orthotopically within the renal capsule. Body weight and tumor growth were followed, and mice were sacrificed according to humane endpoint criteria. To compare tumor growth in s.c. sites and within the abdomen, the tumor weight at sacrifice was divided by the number of days since the inoculation. In the HM-1 model, the mice with intraperitoneal tumor were sacrificed due to build-up of ascites on average six days earlier that the mice with s.c. tumor. In s.c. HM-1 tumor-bearing mice, the reason for sacrifice was tumor ulceration. In the Renca model, the s.c. and intrabursal models were approximately the same length. There was a striking difference in the tumor growth rate (mg/day) in s.c. versus abdominal sites in both models. The growth was 4-5 times faster in the abdominal sites than subcutaneously, highlighting the effect of tumor specific microenvironment. It is easy to understand that having promising results might be easier in a slower growing model. However, since both ovarian and renal cancer show very different growth kinetics within the abdominal cavity, testing drug candidates aimed for those indications in orthotopic models before accessing the clinical trials could give a more relevant evaluation of the potency of the drug candidates.
Citation Format: Mari I. Suominen, Justyna Zdrojewska, Yvonne Konkol, Katja M. Fagerlund, Mervi Ristola, Jukka P. Rissanen. Comparison of subcutaneous and orthotopic tumor growth in syngeneic mouse models of ovarian and renal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 49.
Abstract 563: Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors
Authors: Xu Jian , Zong Qing , Zhu Liang , Liu Qigang , Stann Sasha , Cai Jiaqiang 
Published: April 2023

Abstract
HER3, a member of the HER family, is over-expressed in cancer cells and further elevated after HER2/EGFR/endocrine targeting treatment. YL202 is a novel HER3-targeting antibody-drug conjugate (ADC) structurally composed of a human anti-HER3 antibody, protease-cleavable linker, and a novel topoisomerase I inhibitor. This ADC was prepared using MediLink’s TMALIN platform, a proprietary tumor microenvironment activable linker-payload platform, which achieved a high drug-to-antibody ratio through homogeneously conjugated and favorable hydrophilic linker-payload.
In preclinical studies, YL202 exhibited strong reactivity, highly internalization and potent cytotoxicity toward tumor cells. YL202 also demonstrated significant dose-dependent antitumor activity in cell line- and patient-derived xenograft (CDX and PDX) mouse models representing several cancer types and could induce complete tumor regressions with no observable toxicity. YL202 showed stable PK profile with overlapping ADC and TAb curves in a 28-day cynomolgus monkey study. GLP toxicity studies using cynomolgus monkeys showed that YL202 is well tolerated with calculated therapeutic index (TI, HNSTD/MED) of ~100 for repeat dosing. No lung or platelet toxicity findings were observed at doses up to the maximum tolerated dose (MTD).
Based on these preclinical results, it demonstrates that YL202’s advanced ADC design results in an increased therapeutic margin, and YL201 could be further developed in HER3 positive cancer patients.
Citation Format: Jian Xu, Qing Zong, Liang Zhu, Qigang Liu, Sasha Stann, Jiaqiang Cai. Preclinical development of YL202, a novel HER3-targeting antibody-drug conjugate (ADC) with novel DNA topoisomerase I inhibitor for treatment of solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 563.
Abstract 5883: Computational analysis of immune synapses in melanoma tumor microenvironment
Authors: Liu Zichao , Wang Victor G. , Martinek Jan , Foroughi pour Ali , Zhou Jie , Palucka Karolina , Chuang Jeffrey H. 
Published: April 2023

Abstract
High-resolution multiplexed tissue imaging such as imaging mass cytometry (IMC) has enabled quantitative cell characterization with preserved tissue architecture. However, the subcellular resolution information has not been fully leveraged yet, as most analyses have focused on cellular or compartment level features. Here, we have developed a robust computational approach integrating cellular spatial and molecular features in multiplexed images to quantify immune synapses. Our approach enables computational detection of subcellular enrichment of T cell co-receptors at immune synapses, which are key regulators of T cell functions in the tumor microenvironment (TME). We quantified immune synapse strength between T cells and various antigen-presenting cells in tumor regions in one melanoma whole tissue immunofluorescence dataset and two independent melanoma IMC datasets covering 99 patients. We observed that sub-localizations of immune synapse-related molecules are highly correlated, e.g. CD3 with CD8. These co-localizations are cell type-specific, with differential behaviors in CD4+ or CD8+ T subtypes. Intra-tumoral T-cell-myeloid synapses are associated with improved T cell proliferation (p = 2.8E-4). In addition, we also observed that cytotoxic T cell - melanoma synapses in immune rich regions are stronger in immune checkpoint inhibition therapy responders than in non-responding patients (p = 0.013). Our approach enables computational resolution of spatial inter-cellular interactions within the TME, is applicable across imaging modalities, and facilities assessment of biological and clinical significance.
Citation Format: Zichao Liu, Victor G. Wang, Jan Martinek, Ali Foroughi pour, Jie Zhou, Karolina Palucka, Jeffrey H. Chuang. Computational analysis of immune synapses in melanoma tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5883.
Supp Table S1 from Identifying the Transcriptional Drivers of Metastasis Embedded within Localized Melanoma
Authors: Suresh Shruthy , Rabbie Roy , Garg Manik , Lumaquin Dianne , Huang Ting-Hsiang , Montal Emily , Ma Yilun , Cruz Nelly M , Tang Xinran , Nsengimana Jérémie , Newton-Bishop Julia , Hunter Miranda V. , Zhu Yuxin , Chen Kevin , de Stanchina Elisa , Adams David J. , White Richard M. 
Published: April 2023

<p>Supplementary Table S1. List of genes predictive of metastasis from AVAST-M trial. </p>
Supplementary Figures S1-S11 from Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
Authors: Christmas Brian J. , Rafie Christine I. , Hopkins Alexander C. , Scott Blake A. , Ma Hayley S. , Cruz Kayla A. , Woolman Skylar , Armstrong Todd D. , Connolly Roisin M. , Azad Nilo A. , Jaffee Elizabeth M. , Roussos Torres Evanthia T. 
Published: April 2023

<p>This file contains supplemental figures that includes: FACS gating strategies; QC plots for NanoString cell typing; survival and tumor growth of neu-N mice receiving ENT and ICIs without ï�¡-HER2; circulating MDSCs and absolute numbers of G-MDSCs infiltrating neu-N and Panc02 tumors; G-MDSCs quantified using flow cytometry from neu-N tumors or from hepatic Panc02 metastases; MDSC functional markers by flow cytometry and expression of PD-L1 on G-MDSCs; patterns of myeloid cell functional markers on gene expression profiling; qPCR validation of NanoString, and T cell proliferation and IFNï�§ï€ production within the TME; western blots depicting protein expression levels of STAT3 and phospho-STAT3 and representative proteins from NanoString pathways; the exhaustion state of CD8+ T cells.</p>
Figure S6 from Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
Authors: Wijewarnasuriya Dinali , Bebernitz Christina , Lopez Andrea V. , Rafiq Sarwish , Brentjens Renier J. 
Published: April 2023

<p>(A)	B cells were assessed for CD80 expression by flow cytometry through peripheral blood. *p=0.048 unpaired t test of BM and *p=0.0233 unpaired t test of spleen. Data shown is mean +/- s.e.m. of two independent experiments. (B)	Luminex data showing IL-4 secreting from EL4mCD19 tumor cells. Data shown is mean +/- s.e.m. of two independent experiments. *p=0.002 by unpaired t test. (C)	Flow cytometry demonstrating lack of CD28 expression on CD28-/- T cells. Data shown is representative of two independent experiments. (D)	CAR T cells were co-cultured with EL4mCD19 tumor cells and then assessed for cytotoxicity 4 hours later, using a luciferase killing assay. There was no difference in tumor lysis between CD28-/- or wildtype transduced CAR T cells. Data shown is mean +/- s.e.m. of two independent experiments.</p>
Figure S2 from Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
Authors: Wijewarnasuriya Dinali , Bebernitz Christina , Lopez Andrea V. , Rafiq Sarwish , Brentjens Renier J. 
Published: April 2023

<p>(A)	Media from in vitro co-culture of CAR T cells with EL4mCD19 tumor cells was assessed for IL12p70 on day 7 after CAR T cell treatment. Data shown is mean +/- s.e.m. of two independent experiments. (B)	EL4mCD19 tumor bearing C57BL/6 mice, pretreated with 250mg/kg per mouse of cyclophosphamide day -3, treated i.v. with CAR T cells day 0. Significance determined bylong-rank Mantel-Cox Test, with 95% confidence interval (n=3 per group). *p=0.0224 m1928ï�º compared to m1928ï�º + cyclophosphamide and *p=0.0295 m19ï�º compared to m19ï�º + cyclophosphamide (C)	Flow cytometry demonstrating CD25 expression on CAR T cells prior to injection in terms of percentage and representative flow cytometry plot (ns by ordinary one-way ANOVA). Data shown is mean +/- s.e.m. of three independent experiments (n=3 per group). (D)	CAR T cells were co-cultured with EL4mCD19 tumor cells and assessed for cytotoxicity 4 hours later, using a luciferase killing assay. m1928ï�º, m19ï�ºIL-12, and m1928ï�ºIL-12 CAR T cells showed significantly increased cytotoxicity compared to m19ï�º CAR T cells at E:T ratios of 2:1, 1:1, and 0.5:1. There was no difference in tumor lysis between 19ï�º12 and m1928ï�ºIL-12 CAR T cells (*p=<0.001 by two-way ANOVA). Data shown is mean +/- s.e.m. of three independent experiments. Serum was obtained through retro-orbital bleeds and assessed for IL12p70 through luminex on day 7 after CAR T cell treatment. Data shown is mean +/- s.e.m. of three independent</p>
Data from A Population of TIM4<sup>+</sup>FOLR2<sup>+</sup> Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types
Authors: Bugatti Mattia , Bergamini Marco , Missale Francesco , Monti Matilde , Ardighieri Laura , Pezzali Irene , Picinoli Sara , Caronni Nicoletta , Missolo-Koussou Yoann , Helft Julie , Benvenuti Federica , Vermi William 
Published: April 2023

<div>Abstract<p>TIM4 has previously been associated with antitumor immunity, yet the pattern of expression and the function of this receptor across human cancer tissues remain poorly explored. Here we combined extensive immunolabeling of human tissues with <i>in silico</i> analysis of pan-cancer transcriptomic data sets to explore the clinical significance of TIM4 expression. Our results unveil that TIM4 is expressed on a fraction of cavity macrophages (<sup>CA</sup>TIM4<sup>+</sup>MΦ) of carcinoma patients. Moreover, we uncover a high expression of TIM4 on macrophages of the T-cell zone of the carcinoma-associated tertiary lymphoid structures (<sup>TLS</sup>TIM4<sup>+</sup>MΦ). <i>In silico</i> analysis of a pan-cancer data set revealed a positive correlation between TIM4 expression and markers of B cells, effector CD8<sup>+</sup> T cells, and a 12-chemokine signature defining tertiary lymphoid structure. In addition, <sup>TLS</sup>TIM4<sup>+</sup>MΦ were enriched in cancers displaying microsatellite instability and high CD8<sup>+</sup> T-cell infiltration, confirming their association with immune-reactive tumors. Both <sup>CA</sup>TIM4<sup>+</sup>MΦ and <sup>TLS</sup>TIM4<sup>+</sup>MΦ express FOLR2, a marker of tissue-resident MΦ. However, <sup>CA</sup>TIM4<sup>+</sup>MΦ had a higher expression of the immunosuppressive molecules TREM2, IL10, and TGFβ as compared with <sup>TLS</sup>TIM4<sup>+</sup>MΦ. By analyzing a scRNA sequence data set of tumor-associated myeloid cells, we identified two TIM4<sup>+</sup>FOLR2<sup>+</sup> clusters coherent with <sup>CA</sup>TIM4<sup>+</sup>MΦ and <sup>TLS</sup>TIM4<sup>+</sup>MΦ. We defined specific gene signatures for each subset and found that the <sup>CA</sup>TIM4<sup>+</sup> MΦ signature was associated with worse patient survival. In contrast, <sup>TLS</sup>TIM4<sup>+</sup>MΦ gene signature positively correlates with a better prognosis. Together, these data illustrate that TIM4 marks two distinct macrophage populations with distinct phenotypes and tissue localization and that may have opposing roles in tumor immunity.</p></div>
Supplemental Figure S2 from BRCA1-Associated RING Domain-1 (BARD1) Loss and GBP1 Expression Enhance Sensitivity to DNA Damage in Ewing Sarcoma
Authors: Maurer Lisa M. , Daley Jessica D. , Mukherjee Elina , Venier Rosemarie E. , Julian Claire M. , Bailey Nathanael G. , Jacobs Michelle F. , Kumar-Sinha Chandan , Raphael Haley , Periyapatna Nivitha , Weiss Kurt , Janeway Katherine A. , Mody Rajen , Lucas Peter C. , McAllister-Lucas Linda M. , Bailey Kelly M. 
Published: April 2023

<p>BARD1 loss enhances Ewing sarcoma cell apoptosis in response to niraparib plus radiation in CHLA10 Ewing sarcoma cells.</p>
Ašhab b. ʿAbd al-ʿAzīz (m. 204/820) et l’évolution du maḏhab mālikite (iiie-vie/Ixe-xiie siècle)
Authors: Salah Clément 
Published: April 2023

Abstract
Although recognized as an important legal authority in the formative period of Mālikī legal doctrine (2nd-3rd/8th-9th century), Ašhab b. ʿAbd al-ʿAzīz (d. 204/820) is portrayed in narrative sources after the 4th/10th century as a scholar who diverged from or even contradicted the master’s doctrine, Mālik b. Anas (d. 179/795). This article examines Ašhab’s divergence and independency through the analysis of seven anecdotes consigned in the Mālikī biographical literature between the 4th/10th and 6th/12th centuries. By placing these anecdotes in their political, social and doctrinal contexts of writing we emphasize that: 1. Ašhab’s divergence is a historical construction that is 2. the corollary of the evolution of Mālikī legal doctrine between the 3rd/9th and 6th/12th centuries. In fine, we show that an interconnection exists between the biographical tradition built on Ašhab and the evolution of the Mālikī maḏhab (doctrinal school of law).
Epic Boasts and Empty Threats
Authors: Biles Zachary P. , Watkins Thérèse M. 
Published: April 2023

Abstract
An unnoticed allusion to Homer’s Iliad in Catullus c. 37 contributes to the poem’s recognized military theme by providing a clearer correspondence between figures from epic and those in Catullus’ poem, while also establishing a new framework for analyzing the dynamics of the poet’s verbal attack on his rivals that ultimately implicates him in his own mockery.